Immune Thrombocytopenia, Treatment
Conditions
Brief summary
To evaluate the safety and efficacy of avatrombopag in the treatment of pediatric primary immune thrombocytopenia in patients who have been treated with eltrombopag before and switched to avatrobopag because of poor efficacy, excessive platelet fluctuation or intolerance, or patient preference, economic reasons, and other reasons.
Detailed description
Immune thrombocytopenia (ITP) is an organ-specific autoimmune disease, which is characterized by decreased platelet count and skin and mucosal bleeding. ITP is a kind of disease with increased platelet destruction and impaired platelet production caused by autoimmunity. Conventional treatment of adult ITP includes first-line glucocorticoid and immunoglobulin therapy, second line TPO and TPO receptor agonist, splenectomy and other immunosuppressive treatments (such as rituximab, vincristine, azathioprine, etc.). Eltrombopag is currently the only TPO receptor agonist with indications for pediatric immune thrombocytopenia. However, at present, the treatment response of pediatric ITP is not good, and a considerable number of patients need to switched to other TPO receptor agonist, such as avatrombopag, because of poor efficacy, excessive platelet fluctuation or intolerance, or patient preference, economic reasons, and other reasons. Therefore, the investigators designed this clinical trial to evaluate the efficacy and safety of avatrombopag in the treatment of pediatric immune thrombocytopenia in patients who who have been treated with eltrombopag before and switched to avatrobopag because of different reasons.
Interventions
DRUGAvatrombopag
After enrollment, all subjects receive Avatrombopag treatment. The initial dose of Avatrombopag administration was an oral 10 mg (\<30kg) or 20mg (≥30kg) once daily in all participants. ps. For subjects weighing ≥30kg, the dose can be started from 40mg once daily if the platelet count is \< 10×10\^9/L or if there is severe bleeding or risk of bleeding. Complete blood count including platelet count was done once a week. The dose of Avatrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count was less than 30×10\^9/L for 2 weeks, avatrobopag was gradually increased. If the platelet count was greater than 150 x 10\^9/L, avatrobopag was gradually reduced. If the platelet count \>250×10\^9/L, avatrobopag will be stoped until the platelet count \<100×10\^9/L.
Sponsors
Henan Cancer Hospital
Tianjin Medical University Second Hospital
Tianjin Children's Hospital
The Second Affiliated Hospital of Kunming Medical University
Institute of Hematology & Blood Diseases Hospital, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Age 6-18 years old (including both ends), male and female; * Diagnosed with primary immune thrombocytopenia (ITP); * Patients who had previously received eltrombopag treatment and then converted to avatrombopag treatment because of ineffectiveness (platelet count \< 30×10\^9/L after eltrombopag treatment, or platelet count increased less than 2 times of the basic value, or bleeding) or large platelet fluctuation or due to patient preference, economic reasons and other reasons; * Cardiac function of the New York Society of Cardiac Function ≤ 2; * Understand the study procedure and voluntarily sign the informed consent.
Exclusion criteria
* Secondary thrombocytopenia caused by various reasons, such as connective tissue disorders, bone marrow hematopoietic failure disease, myelodysplastic syndrome, malignancy, drugs, inherited thrombocytopenia, common variable immune deficiency, lymphoma, etc.; * Subjects with primary disease of important organs (liver, kidney, heart, etc.), or with immune system diseases; * Subjects who are known to be allergic to avatrombopag or any of its excipients; * Subjects who had used rituximab within the last 3 months; * Subjects who underwent splenectomy within the last 3 months； * Subjects with a history of abnormal platelet aggregation that may affect the reliability of platelet count measurements； * Any medical history or condition that the investigator deems unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall efficacy response after AVA treatment within 12 weeks | 12 weeks | Overall response rate defined as proportion of subjects with a platelet count ≥ 30 × 10\^9/L and at least 2-fold from baseline without bleeding at the meanwhile within 12 weeks after initial administration in absence of rescue therapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Treatment response-2 | 12 weeks | Number of participants achieving a platelet count ≥ 100×10\^9/L at week 1,2,4,6,8,12 in absence of rescue therapy. |
| Time to Response | 12 weeks | The time required from the start of treatment to the first time a subject's platelet count was greater than or equal to 30×10\^9/L and at least a two-fold increase from the baseline platelet count without bleeding in absence of rescue therapy. |
| Persistent response | 12 weeks | Persistent response defined as proportion of subjects with a platelet count ≥ 30 × 10\^9/L and at least 2-fold from baseline without bleeding for 4 consecutive weeks or more within 12 weeks after initial administration in absence of rescue therapy. |
| Emergency treatment | 12 weeks | The proportion of subjects receiving emergency treatment |
| Reduction of concomitant drug | 12 weeks | Percentage of patients with reduced doses of concomitant drugs at baseline |
| Treatment response-1 | 12 weeks | Number of participants achieving a platelet count ≥ 50×10\^9/L at week 1,2,4,6,8,12 in absence of rescue therapy. |
| Number of participants with clinically significant bleeding as assessed using the bleeding scale for pediatric patients with ITP. | 12 weeks | The bleeding scale for pediatric patients with ITP is a measure of bleeding severity with the following grades: Grade 1 (minor) Minor bleeding, few petechiae (≤100 total) and/or ≤5 small bruises (≤3 cm in diameter), no mucosal bleeding；Grade 2 (mild) Mild bleeding, many petechiae (\>100 total) and/or \>5 large bruises (\>3 cm in diameter), no mucosal bleeding；Grade 3 (moderate) Moderate bleeding, overt mucosal bleeding, troublesome lifestyle；Grade 4 (severe) Severe bleeding, mucosal bleeding leading to decrease in Hb\>2 g/dL or suspected internal hemorrhage； |
| Health-related quality of life survey of subjects(HRQoL)-1 | 12 weeks | In all participants ,use ITP-PAQ (ITP Patient Assessment Questionnaire) to assess the HRQoL before and after treatment. |
| Health-related quality of life survey of subjects(HRQoL)-2 | 12 weeks | In all participants ,use FACIT-F（functional assessment of chronic illness therapy- fatigue）to assess the HRQoL before and after treatment. |
| Health-related quality of life survey of subjects(HRQoL)-3 | 12 weeks | In all participants ,use Kids' ITP tool KIT、to assess the HRQoL before and after treatment. |
| Health-related quality of life survey of subjects(HRQoL)-4 | 12 weeks | In all participants ,use Pediatric Quality of Life Inventory PedsQL to assess the HRQoL before and after treatment. |
| Number of participants with clinically significant bleeding as assessed using the world health organization (WHO) bleeding scale. | 12 weeks | The WHO Bleeding Scale is a measure of bleeding severity with the following grades: grade 0 = no bleeding, grade 1= petechiae, grade 2= mild blood loss, grade 3 = gross blood loss, and grade 4 = debilitating blood loss. |
Countries
China
Contacts
Primary ContactLei Zhang, MD
Backup ContactTing Sun, MD
Outcome results
None listed